Perritt Capital Management Inc decreased its holdings in STRATA Skin Sciences, Inc. (NASDAQ:SSKN – Free Report) by 90.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,000 shares of the medical device company’s stock after selling 90,000 shares during the quarter. Perritt Capital Management Inc’s holdings in STRATA Skin Sciences were worth $31,000 at the end of the most recent quarter.
Separately, Azzad Asset Management Inc. ADV lifted its position in STRATA Skin Sciences by 289.5% during the first quarter. Azzad Asset Management Inc. ADV now owns 67,000 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 49,800 shares during the period. 32.43% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other STRATA Skin Sciences news, CEO Dolev Rafaeli purchased 19,100 shares of STRATA Skin Sciences stock in a transaction dated Monday, July 15th. The stock was purchased at an average price of $3.14 per share, with a total value of $59,974.00. Following the transaction, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at $449,509.84. The purchase was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Uri Geiger bought 230,573 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were bought at an average cost of $3.14 per share, with a total value of $723,999.22. Following the acquisition, the director now owns 1,441,835 shares in the company, valued at $4,527,361.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Dolev Rafaeli purchased 19,100 shares of the business’s stock in a transaction on Monday, July 15th. The shares were bought at an average cost of $3.14 per share, with a total value of $59,974.00. Following the acquisition, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at approximately $449,509.84. The disclosure for this purchase can be found here. Insiders own 40.43% of the company’s stock.
STRATA Skin Sciences Trading Down 0.8 %
STRATA Skin Sciences (NASDAQ:SSKN – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter. The firm had revenue of $8.44 million during the quarter. STRATA Skin Sciences had a negative return on equity of 50.45% and a negative net margin of 25.40%. Research analysts expect that STRATA Skin Sciences, Inc. will post -1 earnings per share for the current year.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.
Recommended Stories
- Five stocks we like better than STRATA Skin Sciences
- How to Choose Top Rated Stocks
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Top Biotech Stocks: Exploring Innovation Opportunities
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- How to Calculate Options Profits
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Want to see what other hedge funds are holding SSKN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STRATA Skin Sciences, Inc. (NASDAQ:SSKN – Free Report).
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.